miR-221 promotes tumorigenesis in human triple negative breast cancer cells von Nassirpour, Rounak, Mehta, Pramod P, Baxi, Sangita M, Yin, Min-Jean

Volltext

A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications von Baxi, Sangita M, Beall, Reed, Yang, Joshua, Mackey, Tim K

Volltext

Impact of Project ECHO Models of Medical Tele-Education: a Systematic Review von McBain, Ryan K., Sousa, Jessica L., Rose, Adam J., Baxi, Sangita M., Faherty, Laura J., Taplin, Caroline, Chappel, Andre, Fischer, Shira H.

Volltext

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90 von MEHTA, Pramod P, WHALEN, Pamela, BAXI, Sangita M, KUNG, Pei-Pei, YAMAZAKI, Shinji, YIN, Min-Jean

Volltext

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells von Baxi, Sangita M, Tan, Wei, Murphy, Sean T, Smeal, Tod, Yin, Min-Jean

Volltext

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity von Fisher, Timothy S., Kamperschroer, Cris, Oliphant, Theodore, Love, Victoria A., Lira, Paul D., Doyonnas, Regis, Bergqvist, Simon, Baxi, Sangita M., Rohner, Allison, Shen, Amy C., Huang, Chunli, Sokolowski, Sharon A., Sharp, Leslie L.

Volltext

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216 von WALLS, Marlena, BAXI, Sangita M, YIN, Min-Jean, MEHTA, Pramod P, LIU, Kevin K.-C, JINJIANG ZHU, ESTRELLA, Heather, CHUNZE LI, ZIENTEK, Michael, QING ZONG, SMEAL, Tod

Volltext

New York State 1115 Demonstration Independent Evaluation: Interim Report von Liu, Harry H, Dick, Andrew W, Qureshi, Nabeel, Baxi, Sangita M, Roberts, Katherine J, Ashwood, J Scott, Guerra, Laura A, Ruder, Teague, Shih, Regina A

Volltext

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design von Cheng, Hengmiao, Li, Chunze, Bailey, Simon, Baxi, Sangita M, Goulet, Lance, Guo, Lisa, Hoffman, Jacqui, Jiang, Ying, Johnson, Theodore Otto, Johnson, Ted W, Knighton, Daniel R, Li, John, Liu, Kevin K.-C, Liu, Zhengyu, Marx, Matthew A, Walls, Marlena, Wells, Peter A, Yin, Min-Jean, Zhu, Jinjiang, Zientek, Michael

Volltext

Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1) von Murphy, Sean T, Alton, Gordon, Bailey, Simon, Baxi, Sangita M, Burke, Benjamin J, Chappie, Thomas A, Ermolieff, Jacques, Ferre, RoseAnn, Greasley, Samantha, Hickey, Michael, Humphrey, John, Kablaoui, Natasha, Kath, John, Kazmirski, Steven, Kraus, Michelle, Kupchinsky, Stan, Li, John, Lingardo, Laura, Marx, Matthew A, Richter, Dan, Tanis, Steven P, Tran, Khanh, Vernier, William, Xie, Zhi, Yin, Min-Jean, Yu, Xiao-Hong

Volltext

Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase von Powell, Noel A., Hoffman, Jennifer K., Ciske, Fred L., Kohrt, Jeffrey T., Baxi, Sangita M., Peng, Yun-Wen, Zhong, Min, Catana, Cornel, Ohren, Jeff, Perrin, Lisa A., Edmunds, Jeremy J.

Volltext

Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase von Powell, Noel A., Hoffman, Jennifer K., Ciske, Fred L., Kaufman, Michael D., Kohrt, Jeffrey T., Quin, John, Sheehan, Derek J., Delaney, Amy, Baxi, Sangita M., Catana, Cornel, McConnell, Patrick, Ohren, Jeff, Perrin, Lisa A., Edmunds, Jeremy J.

Volltext

Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity von Li, Gang, Zhang, Lianglin, Chen, Enhong, Wang, Jianying, Jiang, Xin, Chen, Jeffrey H., Wickman, Grant, Amundson, Karin, Bergqvist, Simon, Zobel, James, Buckman, Dana, Baxi, Sangita M., Bender, Steven L., Casperson, Gerald F., Hu-Lowe, Dana D.

Volltext

Iliac Venous Stenting: Antithrombotic Efficacy of PD0348292, an Oral Direct Factor Xa Inhibitor, Compared With Antiplatelet Agents in Pigs von McBane, Robert D, Leadley, Robert J, Baxi, Sangita M, Karnicki, Krzysztof, Wysokinski, Waldemar

Volltext

Abstract 4467: Targeting both PI3K/mTOR and EGFR pathways leads to synergistic anti-tumor activity in erlotinib resistant non-small-cell lung cancers von Mehta, Pramod P., Baxi, Sangita M., Walls, Marlena, Chen, Stella, Cheng, Hengmiao, Li, Gang, Smeal, Tod, Yin, Min-Jean

Volltext

Abstract 126: miR-221 promotes tumorigenesis in human triple negative breast cancer cells von Yin, Min-Jean, Nassirpour, Rounak, Mehta, Pramod P., Baxi, Sangita M.

Volltext

Abstract 3257: Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor, PF-4989216 von Walls, Marlena, Baxi, Sangita M., Mehta, Pramod P., Epps, Elizabeth, Estrella, Heather, Liu, Kevin KC, Zhu, JinJiang, Li, Chunze, Smeal, Tod, Yin, Min-Jean

Volltext

Abstract 3578: A novel and selective 3-phosphoinositide-dependent kinase-1 inhibitor, PF-5177624, blocks insulin-like growth factor-1 induced tumorigenesis in breast cancer cells von Baxi, Sangita M., Walls, Marlena, Murphy, Sean, Ermolieff, Jacques, Smeal, Tod, Yin, Min-Jean

Volltext

Abstract A50: Targeting 3-phosphoinositide-dependent kinase-1 and mammalian target of rapamycin synergistically inhibits cell proliferation of breast cancer cells von Walls, Marlena, Baxi, Sangita M., Murphy, Sean, Johnson, Teddy W., Tod, Smeal, Yin, Min-Jean

Volltext

Abstract 4479: Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216 von Walls, Marlena, Mehta, Pramod P., Baxi, Sangita M., Liu, Kevin, Li, Chunze, Smeal, Tod, Yin, Min-Jean

Volltext